Joint Pain Forum – News you can use!
Metagenics, Inc. Awarded
Three Patents For The Discovery Of Luduxin™ And Tetrase™, All-Natural
Anti-Inflammatory Agents Derived From Hops
24
Oct 2007
As
edited by Joint-Pain-Forum.com
Metagenics,
Inc., a leading developer and manufacturer of science-based medical
foods and nutraceuticals sold through healthcare practitioners,
announced that it has been awarded three new patents for discoveries
relating to Luduxin™ and Tetrase™, two all-natural selective kinase
response modifier (SKRM) formulations with powerful anti-inflammatory
properties.
U.S. Patent no. 7,270,835 protects the
composition of Luduxin, a proprietary formula consisting of rho
iso-alpha acids (RIAA) derived from hops, as well as the use of Luduxin
in preserving joint health.
U.S. Patent nos.
7,195,785 and 7,205,151 protect the composition of Tetrase, a
proprietary formula comprising of tetrahydro-isohumulone, a tetrahydro
iso-alpha acid derived from hops, as well the use of Tetrase to support
the management of inflammation.
Inflammation has
been identified as the underlying factor in a wide range of health
conditions, including osteoarthritis, autoimmune disease, low bone
mineral density, and metabolic syndrome. The alpha acids and their
derivatives from hops have been shown to selectively inhibit the
pro-inflammatory activities of the COX-2 enzyme without affecting the
housekeeping activities of COX-2 (protection of the gastrointestinal
lining). By comprising reduced iso-alpha acid derivatives, Luduxin and
Tetrase offer effective anti-inflammatory support with high degrees of
predicted safety.
As SKRMs, Luduxin and Tetrase
modulate kinases, the enzymes that chemically modify other proteins and
regulate cellular pathways, particularly those involved in the
transmission of signals within the cell. Kinases also help to regulate
substances that can negatively impact health, including eicosanoids,
cytokines, and damaging free radicals.
----------------------------
Article
adapted by
www.Joint-Pain-Forum.com from original press release.
----------------------------
Clinical studies regarding the safety and efficacy of
SKRMs, conducted by researchers at Metagenics' Functional Medicine
Research Center and its MetaProteomics® Nutrigenomics Research Center,
have been published in leading peer-reviewed nutritional journals. The
company is also continuing to look for additional applications for this
new technology.
"We believe that SKRM technology
represents a new class of therapeutic agents," said Jeffrey S. Bland,
PhD, FACN, Metagenics Chief Science Officer and President of
MetaProteomics®, a wholly-owned subsidiary of Metagenics. "Many
prevalent health issues have been found to have specific underlying
kinase signaling components. Luduxin and Tetrase have shown great
promise as SKRMs for joint health and insulin and triglyceride
management. We're excited by the prospect of discovering further
applications for these powerful compounds."
Metagenics
now includes SKRMs in many of its medical food and nutraceuticals
formulas. For a complete list, please visit http://www.metagenics.com/products.
For more information about the patents or to set-up an interview with
Dr. Bland, contact Josie Lorenzo.
About
Metagenics, Inc.
Metagenics, Inc. is a
life sciences company and leading developer and manufacturer of
science-based nutraceuticals and medical foods sold to healthcare
practitioners worldwide. It is headquartered in San Clemente, Calif.,
with manufacturing and research facilities located in Gig Harbor,
Wash., including the MetaProteomics® Nutrigenomics Research Center and
the Functional Medicine Research CenterSM for human clinical research.
The company demonstrates its commitment to purity and quality through
its certifications for Good Manufacturing Practices (GMP) from the NPA,
NSF International, and TGA.
http://www.metagenics.com.
MEMBERS
AREA
| Site
Map | CONTACT
US
Privacy
| Terms
|
